All In Biotech

Drug Trial Radar · NCT06873516

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Mar 20, 2025

Primary completion

May 29, 2026

Study completion Jun 5, 2026

Sponsor

Lead sponsor
Evommune, Inc.Industry
Sponsor type
Industry
First posted
Mar 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • EVO756Drug

    Dose 1

  • EVO756Drug

    Dose 2

  • EVO756Drug

    Dose 3

  • Placebo controlDrug

    Placebo control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in UAS7Time frame: Week 12

Locations

53 sites in 3 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology Skin Health Center

    Birmingham, Alabama

  • Velocity Clinical Research, Mobile

    Mobile, Alabama

  • Center for Dermatology Clinical Research

    Fremont, California

  • Antelope Valley Clinical Trials

    Lancaster, California

  • Northridge Clinical Trials

    Northridge, California

  • NorthBay Clinical Research

    Santa Rosa, California

  • Integrated Research of Inland

    Upland, California

  • FOMAT Medical Research

    Ventura, California

  • AMR Fort Myers

    Fort Myers, Florida

  • Advanced Clinical Research Institute

    Tampa, Florida

  • Sneeze, Wheeze & Itch Associates LLC

    Normal, Illinois

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • The Iowa Clinic

    West Des Moines, Iowa

  • Hutchinson Clinic

    Hutchinson, Kansas

  • Bluegrass Allergy Care

    Lexington, Kentucky

  • Delricht Research Louisville

    Louisville, Kentucky

  • Delricht Research Louisiana

    Baton Rouge, Louisiana

  • Velocity Clinical Research, Lafayette

    Lafayette, Louisiana

  • Delricht Research

    New Orleans, Louisiana

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Boston Specialists

    Boston, Massachusetts

  • MI Skin Innovations

    Northville, Michigan

  • DelRicht Research - Town Center Dermatology

    Wildwood, Missouri

  • Vitality Clinical Trials

    Woodbury, New York

  • Allergy Partners Clinical Research

    Asheville, North Carolina

  • Delricht Research - Priority Care

    Charlotte, North Carolina

  • Piedmont Healthcare

    Statesville, North Carolina

  • Optima Research Boardman

    Boardman, Ohio

  • DOCS Dermatology Research

    Canal Winchester, Ohio

  • Bernstein Clinical Research Center

    Cincinnati, Ohio

  • Toledo Institute of Clinical Research

    Toledo, Ohio

  • AMR Myrtle Beach

    Myrtle Beach, South Carolina

  • National Allergy and Asthma Research

    North Charleston, South Carolina

  • Delricht Research Smyrna

    Smyrna, Tennessee

  • Austin Regional Clinic ARC Clinical Research

    Austin, Texas

  • Studies in Dermatology

    Cypress, Texas

  • Western Sky Medical Research

    El Paso, Texas

  • Delricht Research - Lockhard Matter Dermatology

    Prosper, Texas

  • AMR Utah

    Layton, Utah

  • Seattle Clinical Research Center

    Seattle, Washington

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.